Ignite Creation Date:
2024-05-06 @ 2:31 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02068040
Status:
COMPLETED
Last Update Posted:
2015-06-03
First Post:
2014-02-18
Brief Title:
Effects of Epicatechin on Functional Capacity Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction HFPEF
Sponsor:
University of California San Diego
Organization:
University of California San Diego
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HFPEF
Brief Summary:
The major goal of this proposal is to characterize the ability of epicatechin which a component of dark chocolate to improve the
1 structural and functional features of skeletal muscle SkM
2 exercise capacity as assessed by VO2 max
3 parameters of diastolic heart function as assessed by echocardiography
We propose that a 3 month treatment with epicatechin through CocoaVia capsules will lead to a significant improvement in exercise capacity and diastolic function
1 structural and functional features of skeletal muscle SkM
2 exercise capacity as assessed by VO2 max
3 parameters of diastolic heart function as assessed by echocardiography
We propose that a 3 month treatment with epicatechin through CocoaVia capsules will lead to a significant improvement in exercise capacity and diastolic function
Detailed Description:
Patient InclusionExclusion Criteria
1 New York Heart Association Class IIIII HF with preserved ejection fraction EF of 50
2 Nonsmokers
3 Subject not taking Coumadin Xarelto Prasugrel or Pradaxa Patients on Plavix for drug eluting stent will not be excluded
4 Ages between 40-65 We will exclude any women of child bearing potential
1 New York Heart Association Class IIIII HF with preserved ejection fraction EF of 50
2 Nonsmokers
3 Subject not taking Coumadin Xarelto Prasugrel or Pradaxa Patients on Plavix for drug eluting stent will not be excluded
4 Ages between 40-65 We will exclude any women of child bearing potential
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None